IMMUNOGLOBULIN-FAB FRAGMENT-BINDING PROTEINS

被引:13
作者
BOUVET, JP
机构
[1] Unité d'Immunologie Microbienne, Institut Pasteur, F-75724 Paris 15
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1994年 / 16卷 / 5-6期
关键词
D O I
10.1016/0192-0561(94)90031-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Five molecules are known to bind the Fab fragments of human immunoglobulins (Ig). Microbial protein A and protein G are primarily Fc-binding molecules but can also bind other structures of the heavy chain, which are located in the variable domain of the third subgroup (V(H)3) and in the first constant domain of IgG (C(H)1,(y) respectively. In contrast, the two other microbial receptors have a sole Ig-binding site, directed to kappa chains (protein L) or to Ig polymers (protein P). Protein Fv is synthesized by human liver cells and released in the digestive lumen, where it forms large complexes with secretory Ig after binding to the V-H domains. These five molecules, in the main, bind cleaved Ig and most of them recognize all classes of antibodies. Bacterial molecules are, or can be, used as reagents to purify and detect Ig and fragments. Furthermore, a possible use in human therapy or vaccination is envisaged, and the human protein Fv is a key-factor in immune protection against intraruminal pathogens of the gut.
引用
收藏
页码:419 / 424
页数:6
相关论文
共 32 条
[1]  
AKERSTROM B, 1989, J BIOL CHEM, V264, P19740
[2]  
BARRETT DJ, 1990, BACTERIAL IMMUNOGLOB, V1, P279
[3]  
BJORCK L, 1988, J IMMUNOL, V140, P1194
[4]   NONIMMUNE VH-BINDING SPECIFICITY OF HUMAN PROTEIN FV [J].
BOUVET, JP ;
PIRES, R ;
QUAN, C ;
ISCAKI, S ;
PILLOT, J .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1991, 33 (04) :381-386
[5]   NONIMMUNE BINDING OF HUMAN PROTEIN-FV TO IMMUNOGLOBULINS FROM VARIOUS MAMMALIAN AND NONMAMMALIAN SPECIES [J].
BOUVET, JP ;
PIRES, R ;
CHARLEMAGNE, J ;
PILLOT, J ;
ISCAKI, S .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1991, 34 (04) :491-496
[6]  
BOUVET JP, 1993, J IMMUNOL, V151, P2562
[7]  
BOUVET JP, 1990, J IMMUNOL, V145, P1176
[8]  
BOUVET JP, 1990, J IMMUNOL, V145, P3944
[9]  
BOYLE M D P, 1990, P295
[10]  
DECHATEAU M, 1993, SCAND J IMMUNOL, V37, P399